866-997-4948(US-Canada Toll Free)

Systemic Mastocytosis - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 136 Pages

Systemic Mastocytosis - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Mastocytosis - Pipeline Review, H2 2017, provides an overview of the Systemic Mastocytosis (Gastrointestinal) pipeline landscape.

Systemic mastocytosis is a disorder where mast cells are abnormally increased in multiple organs including the bone marrow. Symptoms include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing and musculoskeletal pain. Treatment includes antihistamines and more aggressive forms of Systemic mastocytosis require interferon or chemotherapeutic agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Mastocytosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Systemic Mastocytosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Mastocytosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I and Preclinical stages are 1, 5, 3 and 1 respectively.

Systemic Mastocytosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Mastocytosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Mastocytosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Mastocytosis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Systemic Mastocytosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Systemic Mastocytosis - Overview 6
Systemic Mastocytosis - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 10
Systemic Mastocytosis - Therapeutics Assessment 11
Assessment by Target 11
Assessment by Mechanism of Action 13
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Systemic Mastocytosis - Companies Involved in Therapeutics Development 19
AB Science SA 19
AbbVie Inc 19
Arog Pharmaceuticals Inc 20
Blueprint Medicines Corp 20
Bristol-Myers Squibb Co 21
Deciphera Pharmaceuticals LLC 21
Patara Pharma Inc 21
Seattle Genetics Inc 22
Stemline Therapeutics Inc 22
Systemic Mastocytosis - Drug Profiles 24
AK-002 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
BLU-285 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
brentuximab vedotin - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
crenolanib besylate - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
cromolyn sodium - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
dasatinib - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
DCC-2618 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
ibrutinib - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
masitinib - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
SL-401 - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
Systemic Mastocytosis - Discontinued Products 125
Systemic Mastocytosis - Product Development Milestones 126
Featured News & Press Releases 126
Aug 02, 2017: Blueprint Medicines Provides Update on Clinical Program of its Cancer Drug, BLU-285 126
Mar 27, 2017: Blueprint Medicines to Present on BLU-285 at Upcoming Scientific Conferences 127
Dec 04, 2016: Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis 127
Nov 03, 2016: Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at 2016 ASH Annual Meeting 129
Oct 31, 2016: Deciphera Pharmaceuticals to Present Clinical Data on DCC-2618 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 130
Oct 28, 2016: Blueprint Medicines to Present Preclinical Data and Provide Enrollment Updates for Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at ECNM Annual Meeting 2016 131
Sep 15, 2016: Allakos Begins Clinical Trials of AK002 in Patients with Systemic Mastocytosis 131
Sep 10, 2015: Blueprint Medicines Receives FDA Authorization to Advance Novel Drug Candidate into Clinical Trial for Systemic Mastocytosis 132
Dec 08, 2014: Blueprint Medicines Debuts Comprehensive Preclinical Data Set on First Selective Drug for Patients with Systemic Mastocytosis at 2014 American Society of Hematology Annual Meeting 132
Dec 09, 2012: Seattle Genetics Highlights Adcetris Data In CD30-Positive Non-Hodgkin Lymphomas And Other Malignancies From Multiple Presentations At ASH Annual Meeting 133
Appendix 135
Methodology 135
Coverage 135
Secondary Research 135
Primary Research 135
Expert Panel Validation 135
Contact Us 135
Disclaimer 136

List of Tables
Number of Products under Development for Systemic Mastocytosis, H2 2017 7
Number of Products under Development by Companies, H2 2017 9
Products under Development by Companies, H2 2017 10
Number of Products by Stage and Target, H2 2017 12
Number of Products by Stage and Mechanism of Action, H2 2017 14
Number of Products by Stage and Route of Administration, H2 2017 16
Number of Products by Stage and Molecule Type, H2 2017 18
Systemic Mastocytosis - Pipeline by AB Science SA, H2 2017 19
Systemic Mastocytosis - Pipeline by AbbVie Inc, H2 2017 20
Systemic Mastocytosis - Pipeline by Arog Pharmaceuticals Inc, H2 2017 20
Systemic Mastocytosis - Pipeline by Blueprint Medicines Corp, H2 2017 20
Systemic Mastocytosis - Pipeline by Bristol-Myers Squibb Co, H2 2017 21
Systemic Mastocytosis - Pipeline by Deciphera Pharmaceuticals LLC, H2 2017 21
Systemic Mastocytosis - Pipeline by Patara Pharma Inc, H2 2017 22
Systemic Mastocytosis - Pipeline by Seattle Genetics Inc, H2 2017 22
Systemic Mastocytosis - Pipeline by Stemline Therapeutics Inc, H2 2017 23
Systemic Mastocytosis - Discontinued Products, H2 2017 125

List of Figures
Number of Products under Development for Systemic Mastocytosis, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products by Top 10 Targets, H2 2017 11
Number of Products by Stage and Top 10 Targets, H2 2017 11
Number of Products by Top 10 Mechanism of Actions, H2 2017 13
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 13
Number of Products by Routes of Administration, H2 2017 15
Number of Products by Stage and Routes of Administration, H2 2017 15
Number of Products by Molecule Types, H2 2017 17
Number of Products by Stage and Molecule Types, H2 2017 17

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *